Monday, September 01, 2014 8:46:36 PM
Miles,
I agree completely, except for having bought a small position here already.
If I recall, and I'm sure you'll correct me if I have it wrong, B was going to be just the first in class of these difensin-mimetic antibiotics deriving from the PYMX IP. I think I also recall that both dads and the rest of the family own major portions of the NNAB stock.
Here comes the blue-sky part.
It would not be entirely far fetched to assume that no development of the second or third in class defensin mimetics will take place at CTIX unless they get on a sound financial footing.
Further, if the dads decide to sell CTIX and B + K + P to a major pharma they may have to continue working for the pharma for a while, but I have to imagine they may not have to sell the rest of the IP to that pharma.
So, B2, B3 and the autism compound could go elsewhere. Where better than NNAB?
Of course, if there is no buyout, only parnerships, Leo and Menon retain control of an ever-growing CTIX and my supposition is false. All the drugs get developed down the road by CTIX - as long as the patents haven't expired.
There is also the possibility of out-licensing P2 P3 etc, to another entity with the resources to develop them.
Just a thought.
Steve
I agree completely, except for having bought a small position here already.
If I recall, and I'm sure you'll correct me if I have it wrong, B was going to be just the first in class of these difensin-mimetic antibiotics deriving from the PYMX IP. I think I also recall that both dads and the rest of the family own major portions of the NNAB stock.
Here comes the blue-sky part.
It would not be entirely far fetched to assume that no development of the second or third in class defensin mimetics will take place at CTIX unless they get on a sound financial footing.
Further, if the dads decide to sell CTIX and B + K + P to a major pharma they may have to continue working for the pharma for a while, but I have to imagine they may not have to sell the rest of the IP to that pharma.
So, B2, B3 and the autism compound could go elsewhere. Where better than NNAB?
Of course, if there is no buyout, only parnerships, Leo and Menon retain control of an ever-growing CTIX and my supposition is false. All the drugs get developed down the road by CTIX - as long as the patents haven't expired.
There is also the possibility of out-licensing P2 P3 etc, to another entity with the resources to develop them.
Just a thought.
Steve
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent BIVI News
- Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV • ACCESS Newswire • 10/17/2025 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2025 09:05:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2025 08:25:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2025 09:09:59 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/08/2025 04:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2025 12:52:40 PM
- Biovie shares climb as Alzheimer’s drug shows promising age deceleration effects • IH Market News • 07/24/2025 03:10:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2025 08:49:55 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/22/2025 12:31:37 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/11/2025 09:19:50 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/03/2025 09:01:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/27/2025 09:20:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/24/2025 09:20:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/02/2025 08:16:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2025 09:15:33 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/08/2025 09:20:30 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 05/07/2025 09:20:08 PM
